Recently, two larger epidemiological studies on the association between sclerostin gene polymorphisms, which are associated with a low sclerostin expression phenotype (thus mimicking therapeutic intervention in sclerostin levels) and cardiovascular disease have been published. This evidence concerns the gene SOST and cardiovascular disorder.